The Ras Inhibitor Farnesylthiosalicylic Acid as a Potential Therapy for Neurofibromatosis Type 1

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-06-0792
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Inhibition of Contact Sensitivity by Farnesylthiosalicylic Acid-Amide, a Potential Rap1 Inhibitor

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2011English

Suppression of Lung Cancer Tumor Growth in a Nude Mouse Model by the Ras Inhibitor Salirasib (Farnesylthiosalicylic Acid)

Molecular Cancer Therapeutics
Cancer ResearchOncology
2007English

Suppression of Survivin Expression in Glioblastoma Cells by the Ras Inhibitor Farnesylthiosalicylic Acid Promotes Caspase-Dependent Apoptosis

Molecular Cancer Therapeutics
Cancer ResearchOncology
2006English

Neurofibromatosis Type 1 Alternative Splicing Is a Key Regulator of Ras Signaling in Neurons

Molecular and Cellular Biology
Cell BiologyMolecular Biology
2014English

Phase I Study of S-Trans, Trans-Farnesylthiosalicylic Acid (Salirasib), a Novel Oral RAS Inhibitor in Patients With Refractory Hematologic Malignancies

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2015English

Neurofibromatosis Type 1 (NF1)

Atlas of Genetics and Cytogenetics in Oncology and Haematology
Cancer ResearchOncologyGeneticsHematology
2011English

Malignancy in Neurofibromatosis Type 1

Oncologist
Cancer ResearchMedicineOncology
2000English

Health Supervision for Children With Neurofibromatosis Type 1

Pediatrics
Child HealthPediatricsPerinatology
2019English

Neurofibromatosis Type 1: Modeling CNS Dysfunction

Journal of Neuroscience
Neuroscience
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy